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Abstract
Background: It is known that continuous venonenous hemofiltration (CVVH) does not affect the plasma level of
neutrophil gelatinase-associated lipocalin (pNGAL) in acute kidney injury (AKI) patients. However, because of the
unique pathophysiology underlying AKI caused by sepsis, the effect of CVVH on pNGAL in this clinical setting is less
certain. The purpose of this study was to determine the effect of CVVH on pNGAL in sepsis-induced AKI patients.
Methods: Between August 1, 2014, and December 31, 2014, 42 patients with sepsis-induced AKI underwent CVVH
in the general intensive care unit of our institution and were consecutively enrolled in this study. Prefilter, postfilter,
and ultrafiltrate pNGAL measurements were taken at the initiation of continuous renal replacement therapy (CRRT)
and repeated after 2, 4, 8, and 12 h (T0, T2h, T4h, T8h, and T12h, respectively). The mass transfer, plasma clearance,
and sieving coefficient were calculated based on the mass conservation principle.
Results: Following CVVH initiation, we found that pNGAL in the ultrafiltrate decreased significantly (P = 0.013);
however, levels at the inlet and outlet showed no significant change (P > 0.05 for both). Furthermore, there was no
change in the total mass removal rate, total mass adsorption rate, and plasma clearance over time (P > 0.05 for all),
and a significant decrease in the sieving coefficient (P = 0.007) was seen.
Conclusions: The results of this study show a limited effect of CVVH on pNGAL in sepsis-induced AKI patients. This
suggests that pNGAL may be used as an indicator of renal progression in these patients. However, a larger study to
confirm these findings is needed.
Trial registration: ClinicalTrials.gov, NCT02536027. Retrospectively registered on 20th August 2015.
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Background
Acute kidney injury (AKI) is a leading cause of sepsis-
related deaths in the intensive care unit (ICU), accounting
for approximately half of all cases [1, 2]. Early diagnosis of
AKI and timely prediction of renal recovery are two of the
primary challenges in the field of AKI research. On one
hand, because serum creatinine (SCr) does not accurately
reflect the glomerular filtration rate (GFR), it is considered
a late marker for AKI [3, 4]. On the other hand, the
Beginning and Ending Supportive Therapy for the Kidney
study suggested that a urine output >500 mL/d is the most
important predictor of successful discontinuation of con-
tinuous venovenous hemofiltration (CVVH). However, the
urinary output is often affected by clinical interventions
(e.g., diuretic administration) [5]. Therefore, it is of great
importance to discover a reliable biomarker for the early
diagnosis of AKI that reflects the renal function of patients
when they are receiving CVVH.
A growing body of evidence indicates that septic AKI
is a different pathophysiological entity than other types
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of AKI. As such, the assessment and prognostic tools
used to assess septic AKI need careful consideration,
and this process has already started [6, 7]. In the last
decade, a number of novel biomarkers to help diagnose
AKI at an early stage and accurately predict renal recov-
ery have been studied intensively. Plasma neutrophil
gelatinase-associated lipocalin (pNGAL), a 25 kDa pro-
tein covalently bound to human neutrophil gelatinase,
has been confirmed as a reliable biomarker for AKI oc-
currence and recovery from infectious disease [8–11].
However, patients requiring CVVH were excluded from
most of these previous studies because it was thought
that pNGAL concentration might change during CVVH
through clearance as well as by release in the filter. A re-
cent article by Schilder [12] reported that CVVH did not
affect pNGAL in AKI patients due to low filter clear-
ance. Another small series (n = 3) also reported that
pNGAL was not significantly cleared during CVVH [13].
However, it remains unclear whether this also applies to
septic AKI. The aim of the present study was to deter-




The ethical committee of the First Peoples’ Hospital
approved this study, and it was registered with the
US National Institutes of Health Clinical Trials Register
(NCT02536027). Patients or their next of kin signed
informed consent forms of their own accord after being
fully informed of all the relevant details of the study. All
patients with septic acute kidney injury (SAKI) undergo-
ing CVVH in the general ICU were consecutively enrolled
in the study during the period from August 1, 2014,
to December 31, 2015.
Inclusion and exclusion criteria
Adult (>18 years) patients with SAKI undergoing con-
tinuous renal replacement therapy (CRRT) were assessed
for inclusion. The urine output and SCr parameters were
used from the 2012 Kidney Disease Improving Global
Outcomes criteria [14], which were based on the Risk,
Injury, Failure, Loss, End-stage/Acute Kidney Injury
Network definitions. These included an absolute increase
in SCr of ≥26.4 μmol/L over 48 h, a percentage increase in
SCr of ≥50 % from baseline over the previous 7 days, or
urine output ≤0.5 mL/(kg · h) for a period of ≥6 h. Further-
more, based on the diagnostic criteria of the 2001 Inter-
national Sepsis Definition Conference [15], sepsis was
defined as a systemic, deleterious host response to infection
resulting in a systemic inflammatory response syndrome
characterized by two or more of the following (definitions
in parentheses): hypothermia or fever (body temperature
<36 °C or >38.5 °C), tachycardia (>90 beats/min), tachypnea
(>20 breaths/min or PaCO2 < 32 mm Hg on mechanical
ventilation), leukocytosis (>12,000/mm3), leukopenia
(<4000/mm3), or increased immature band forms (>10 %).
The following patients were excluded: (1) those with
end-stage renal disease; (2) those with a history of renal
transplant; (3) those with cancer; (4) those with acquired
immunodeficiency syndrome; and (5) who had under-
gone high-dose steroid treatment.
CRRT procedure
CVVH was performed with a Fresenius 4008S CRRT plus
machine (Fresenius Medical Care, Homburg, Germany)
after establishing venous access in the femoral or jugular
vein with an 11- to 14-Fr double-lumen catheter. The
hemodiafilter membrane used was Fresenius AV600S
(Fresenius, Homburg, Germany). In principle, patients
were hemofiltered at a blood flow rate of 180–220 mL/
min in 2 L postdilution CVVH mode. An initial dose of
heparin 400–1000 IU/h was given, with adjustment of the
heparin infusion based on patient coagulation function.
Anticoagulation also included a postfilter infusion of pro-
tamine, with a ratio of heparin 100 IU to protamine 1 mg.
Data collection
Baseline patient data (age, gender, etiological factors,
and underlying diseases) were collected on patient ad-
mission to the ICU. The white blood cell (WBC) count,
C-reactive protein (CRP), and procalcitonin (PCT) levels
were obtained at CVVH initiation. Clinical data neces-
sary to calculate sequential organ failure assessment
(SOFA) and acute physiology and chronic health evalu-
ation II (APACHE II) scores were also collected.
Measurement of plasma NGAL
Prefilter, postfilter, and ultrafiltrate samples were obtained
at the beginning of CRRT and again after 2, 4, 8, and 12 h
(T0, T2h, T4h, T8h, and T12h, respectively). The NGAL
level was measured using an enzyme-linked immuno-
sorbent assay (Lipocalin2/NGAL Duoset, DY1757, R&D
Systems, UK) with a measurable range of 20–3000 ng/mL.
Calculation
Based on the mass conservation principle, NGAL total
mass removal rate (Mtr), mass adsorption rate (Mad),
sieving coefficient (SC), and plasma clearance (PC) were
calculated using the following formulas [12]:
Qi ¼ Qb  1 – Hctð Þ
Qo ¼ Qi
Mi ¼ Qi  C i
Mo ¼ Qo  Co
Muf ¼ Quf  Cuf




SC ¼ 2  Cuf= C þ Coð Þ
Abbreviations:
Ci: Concentration in inlet plasma before addition of
replacement fluid (ng/mL)
Co: Concentration in outlet plasma (ng/mL)
Cuf: Concentration in the ultrafiltrate (ng/mL)
Qb: Inlet blood flow rate (mL/min)
Qi: Inlet plasma flow rate (mL/min)
Qo: Outlet plasma flow rate (mL/min)
Quf: Ultrafiltration flow rate (mL/min)
Mi: Mass inlet rate (ng/min)
Mo: Mass outlet rate (ng/min)
Muf: Mass ultrafiltration rate (ng/min)
Mtr: Mass removal rate (ng/min)
Mad: Mass adsorption rate (ng/min)
RF: Replacement fluid flow rate (ng/min)
SC: Sieving coefficient
Statistical analysis
Continuous variable data with normal distributions
were provided as mean ± standard deviation (SD). Non-
normally distributed continuous variable data were pre-
sented as median (25th, 75th percentiles). The Kruskal–
Wallis test was used to compare measured and calculated
data. Qualitative variable data were expressed as fre-
quencies (n) and percentages (%). Statistical analyses
were conducted using IBM SPSS 19.0 (SPSS; Chicago,
IL, USA), and a P value of <0.05 was considered sta-
tistically significant.
Results
Forty-eight consecutive subjects were screened. Of these,
six subjects were excluded: three patients did not receive
heparin anticoagulation due to severe coagulation disor-
ders; one required an emergency operation due to active
bleeding; one was excluded due to his next of kin with-
drawing consent; and one patient died during CVVH,
and his data were thus incomplete. Therefore, this study
was completed for 42 patients, 24 males and 18 females,
aged 53.2 ± 17.3 years. In 34 patients, venous access was
established via the femoral vein, and in 8 patients, it was
established via the jugular. Eighteen patients (42.9 %)
died in the ICU. Nonsurvivors showed significantly
higher median pNGAL at the inlet than survivors at T0
(1112 [323–1869] ng/mL versus 772 [121–1548] ng/mL,
P = 0.033). Basic patient characteristics and clinical data
at T0 are summarized in Tables 1 and 2, respectively.
All samples had detectable NGAL levels. Following initi-
ation of CVVH, pNGAL in the ultrafiltrate decreased sig-
nificantly (P = 0.013), whereas levels at the inlet and outlet
did not change (P > 0.05 for both; Fig. 1). Furthermore, no
change was seen in the total mass removal rate, total mass
adsorption rate, and PC over time (P > 0.05 for all), while
the SC significantly decreased (P = 0.007; Fig. 2). Table 3
presents data for the total mass removal rate, mass
adsorption rate, SC, and PC of NGAL during CVVH.
Table 1 Clinical characteristics
Clinical characteristics Patients with SAKI (n = 42)
Age (year) 53.2 ± 17.3
Male gender (n, %) 28 (66.7)
Etiological factors (n, %)
Abdominal infection 18 (42.9)
Pulmonary infection 12 (28.6)
Trauma-related infection 10 (23.8)
Urinary tract infection 2 (4.8)




Coronary heart disease 6 (14.3)
Normally distributed quantitative data are presented as mean ± SD. Qualitative
data are presented as n (%). SAKI septic acute kidney injury, COPD chronic
obstructive pulmonary disease
Table 2 Biological data at T0
Biological data Patients with SAKI (n = 42)
MAP (mm Hg) 67.2 ± 32.5
PaO2/FiO2 192 (131, 352)
SOFA 10 ± 3
APACHE II 18 (14, 21)
WBC count (×109/L) 14.5 (11.3, 18.9)
Hct (%) 25.0 ± 5.3
PLT (×109/L) 98 (46, 219)
CRP (mg/dL) 146.7 (53.3, 189.9)
PCT (ng/mL) 13.21 (3.02, 38.81)
SCr (μmol/L) 242 (189, 367)
BUN (mmol/L) 12.3 ± 8.4
Fibrinogen (g/L) 5.9 ± 3.2
Albumin (g/L) 28 ± 7.5
Lactate (mmol/L) 5.4 (2.2, 7.6)
Normally distributed quantitative data are presented as mean ± SD. Non-normally
distributed quantitative data are presented as median (25th, 75th percentiles).
Qualitative data are presented as n (%). APACHE II acute physiology and
chronic health evaluation II, BUN blood urea nitrogen, COPD chronic obstructive
pulmonary disease, CRP C-reactive protein, Hct hematocrit, MAP mean arterial
pressure, PCT procalcitonin, PLT platelets, SAKI septic acute kidney injury,
SOFA sequential organ failure assessment, SCr serum creatinine, WBC white
blood cell
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Discussion
Results of this study demonstrate that CVVH did not
significantly affect the plasma concentration of NGAL in
patients with septic AKI: pNGAL did not decline, and
NGAL clearance was lower than expected. There is con-
siderable evidence that the underlying pathophysiology
of septic AKI is unique in comparison with those of
other types of AKI. Specifically, NGAL levels differ
significantly between AKI patients with and without sep-
sis [16]. Therefore, it is reasonable to surmise that the
clearance and production of NGAL during CVVH may
be different than in other types of AKI. However, this
study yielded results in accordance with the previous
studies on AKI from other causes [12, 13]. A three-case
study demonstrated that CVVH did not substantially
affect pNGAL concentration in AKI patients [12]. An-
other study by Schilder and colleagues [13] also re-
ported no net removal of NGAL during CVVH in
patients with AKI. These findings indicate that CVVH
does not affect the levels of NGAL in AKI patients with
or without sepsis.
Contrary to the present study results, however,
Donadio recently suggested that dialytic techniques
and membranes can remove pNGAL and affect its ac-
curacy as a biomarker of AKI [17]. They reported
that low-flux dialysis (F8; Fresenius, Bad Homburg,
Germany) did not remove pNGAL (which increased
by 9.1 ± 24.4 %), whereas high-flux dialysis (N190 FH;
Nipro, Osaka, Japan; triacetate cellulose membrane,
surface area 1.9 m2; ultrafiltration rate 8474 mL/h per
100 mm Hg) decreased pNGAL significantly (P < 0.0001).
What is more, they found that the reduction ratio of
pNGAL with hemodiafiltration using a polyphenylene
membrane (surface area 2.0 m2) and an ultrafiltration
rate of 6800 mL/h per 100 mm Hg (Phylther; Bellco,
Mirandola, Italy) or an acrylonitril and natrium metallyl-
sulfone copolymer membrane (surface area 2.15 m2) and
Fig. 1 Plasma NGAL concentration over time at the inlet and
outlet, and in the ultrafiltrate, after the initiation of CVVH in
patients with SAKI. Levels of pNGAL at the inlet and outlet did
not change (P > 0.05), whereas in the ultrafiltrate, the level
decreased over time (P = 0.013). CVVH, continuous venovenous
hemofiltration; NGAL, neutrophil gelatinase-associated lipocalin;
SAKI, septic acute kidney injury
Fig. 2 Total mass removal rate, mass adsorption rate, sieving coefficient, and clearance of pNGAL during CVVH. The total mass removal rate (a),
mass adsorption rate (b), and plasma clearance (d) did not change over time, but the sieving coefficient (c) decreased significantly (P = 0.007).
CVVH, continuous venovenous hemofiltration; NGAL, neutrophil gelatinase-associated lipocalin
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an ultrafiltration rate of 6500 mL/h per 100 mm Hg
(Nephral 500; Gambro, Lund, Sweden) were higher than
those seen with high-flux dialysis (52.1 ± 26.7 % vs 26.6 ±
26.1 %, P = 0.053). In the present study, CVVH treatments
were performed using a polysulfone membrane (AV600s;
Fresenius, Homburg, Germany; surface area of 1.35 m2),
with a cutoff of approximately 30 kDa and an ultrafiltra-
tion rate of 4000 mL/h per 100 mm Hg. It is conceivable
that membrane characteristics may impact NGAL re-
moval significantly. In clinical practice, in view of different
membrane characteristics among different CRRT ma-
chines, the result should be discriminatory. For example,
the efficacy of NGAL removal using a AN69 membrane
(M100 set; Prismaflex, Hechingen, Germany) with a sur-
face area of 0.9 m2 may be lower than that using a high-
flux membrane. Therefore, further studies are needed to
confirm whether the membrane type as well as the dialytic
techniques used affect the clearance of NGAL in patients
with septic AKI.
The present study had certain limitations. First, it was
a single-center observational study with a small cohort
of patients, which increased the chance of a type II
error. A larger study is required to confirm the present
finding. Second, the impact of anticoagulation was not
considered. Schilder [12] reported that pNGAL was not
affected by the anticoagulation of patients with AKI.
However, another study demonstrated that sepsis was
frequently associated with the pathological activation of
the coagulation system [18]. Thus, it remains unclear
whether or not pNGAL is affected by anticoagulation in
patients with septic AKI receiving CVVH.
Conclusions
This study confirmed that pNGAL does not significantly
decrease during CVVH in septic AKI. This means that
the impact of CVVH does not need to be considered
when pNGAL is used to judge renal progression in pa-
tients with septic AKI who are receiving CVVH.
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Table 3 Total mass removal rate, Mass adsorption rate, Sieving coefficient, and Plasma clearance of NGAL during CVVH
T0 T2 T4 T8 T12
Ci (ng/mL) 879 (733, 1466) 850 (685, 1525) 859 (688, 1496) 847 (689, 1417) 844 (694, 1405)
Co (ng/mL) 867 (697, 1451) 845 (703, 1332) 890 (661, 1416) 834 (689, 1326) 819 (646, 1415)
Cuf (ng/mL) 32.2 (26.7, 40.8) 30.3 (23.6, 34.9) 27.7 (24.1, 31.9) 26.1 (21.2, 30.1) 24.0 (20.1, 28.0)
Mi (μg/min) 107 (94, 183) 104 (97, 194) 105 (89, 197) 105 (91, 182) 110 (88, 180)
Mo (μg/min) 104 (92, 181) 107 (88, 170) 109 (85, 182) 107 (89, 170) 109 (85, 172)
Muf (ng/min) 2189 (1330, 2748) 1807 (1181, 3363) 1888 (1309, 2312) 2048 (1129, 3693) 1397 (1018, 3471)
Mtr (ng/min) 1430 (239, 4914) 1502 (−2500, 4801) 3240 (593, 5544) 3024 (−82, 5360) 4620 (2540, 6687)
Mad (ng/min) −313(−2576, 3470) −1369 (−5611, −1682) 1651 (−1494, 3308) 354 (−2195, 3201) 2216 (507, 5104)
SC 0.21 (0.17, 0.26) 0.19 (0.16, 0.22) 0.17 (0.15, 0.21) 0.16 (0.13, 0.20) 0.16 (0.12, 0.18)
Clearance 2.05 (0.39, 3.57) 1.45 (−3.15, 4.28) 3.74 (0.73, 6.09) 3.56 (−0.45, 5.80) 4.57 (1.85, 8.94)
Data are presented as median (25th, 75th percentiles). CVVH continuous venovenous hemofiltration, NGAL neutrophil gelatinase-associated lipocalin, Ci concentration
in inlet plasma before addition of replacement fluid, Co concentration in outlet plasma, Cuf concentration in the ultrafiltrate, Mad mass adsorption rate,
Muf mass ultrafiltration rate, Mi mass inlet rate, Mo mass outlet rate, Mtr mass removal rate, SC sieving coefficient
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